Dental risk factors for osteonecrosis of the jaws: A CONDOR case-control study

Clinical Oral Investigations

Volumn 17, Issue 8, 2013, Pages 1839-1845

  Barasch, A ^a   Cunha Cruz, J ^b   Curro, F ^c   DeRouen, T ^b   Gilbert, G H ^d   Hujoel, P ^b,e   Safford, M M ^f   Vena, D A ^e   Voinea Griffin, A E ^d   Wu, H ^e  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Univ of Alabama School of Dentistry   (United States)

^e EMMES Corp   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Dental diagnosis; Dental treatment; Jaws; Osteonecrosis; Risk factors

Indexed keywords

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CASE CONTROL STUDY; HUMAN; RISK FACTOR;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CASE-CONTROL STUDIES; HUMANS; RISK FACTORS;

EID: 84886590601     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-012-0880-4     Document Type: Article

References (25)

1. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P (2005) Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 34: 613-617.
2. Badros A, Weikel D, Salama A et al (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: 945-952.
3. Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587.
4. Farrugia MC, Summerlin DJ, Krowiak E et al (2006) Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116: 115-120.
5. Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21: 4253-4254.
6. Rosenberg T, Ruggiero S (2003) Osteonecrosis of the jaws associated with the use of bisphosphonates. Paper presented at: 85th Annual American Association of Oral and Maxillofacial Surgeons Meeting; September 10-13, 2003; Orlando, FL.
7. Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61: 1104-1107.
8. Devogelaer JP (2000) Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 12: 331-335.
9. Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544.
10. Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13: 4482-4486.
11. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32: 94-124.
12. Moreira MS, Katayama E, Bombana AC, Marques MM (2005) Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue: a pilot study. Dent Traumatol 21: 329-335.
13. Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2010) Importance of microcracks in etiology of bisphosphonates-realted osteonecrosis of the jaw: a possible pathogenic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 4: 271-284.
14. Barasch A, Cunha-Cruz J, Curro FA et al (2011) Risk factors for osteonecrosis of the jaw: a case-control study from the CONDOR Dental PBRN. J Dent Res 90: 439-444.
15. Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761.
16. Rustemeyer J, Bremerich A (2010) Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Invest 14: 59-64.
17. Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
18. D'Agostino RB Jr (1998) Propensity score methods for bias reduction for the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281.
19. Rubin DB, Thomas N (2000) Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 95: 573-585.
20. Bagan JV, Murillo J, Jimenez Y et al (2005) Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34: 120-123.
21. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N (2012) Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int; Epub ahead of print.
22. Otto S, Abo-Id MH, Fedele S et al (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic cincidence-a multi-centre study. J Craniomaxillofac Surg 39: 272-277.
23. Richards D (2008) Guidelines for bisphosphonate-associated osteonecrosis of the jaw. Evid Based Dent 9: 101-102.
24. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67(5 Suppl): 2-12.
25. Eisbruch A, Harris J, Garden AS et al (2010) Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 76: 1333-1338.